CASI - CASIファ―マシュ―ティカルズ (CASI Pharmaceuticals Inc.) CASIファ―マシュ―ティカルズ

 CASIのチャート


 CASIの企業情報

symbol CASI
会社名 CASI Pharmaceuticals Inc. (CASIファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エントレメッド(EntreMed Inc.)は臨床段階の医薬品会社。同社の薬品候補「ENMD-2076」はがん治療用のオーロラAと血管新生キナーゼ阻害剤である。「ENMD-2076」は進行性固形腫瘍、多発性骨髄腫、白血病の患者での第I相試験を完了した、プラチナ抵抗性再発卵巣癌の患者での多施設共同第II相試験を行うためにデータを完了している。同社のほかの薬品候補は関節リウマチの治療用の「2-methoxyestrdiol」(2ME2 Panzem)、「ENMD-1198」及び「MKC-1」を含む。「ENMD-2076」は新規経口で有効な、オーロラAと血管新生キナーゼ阻害剤であり、癌や炎症性疾患にリンクされるオーロラAおよび複数のチロシンキナーゼに対して強力な活性を有する。  CASIファ―マシュ―ティカルズは、米国の製薬会社。癌および他の疾患の治療薬を開発する。臨床段階にある主要な医療薬候補は、癌治療のオ―ロラAと血管新生キナ―ゼ阻害剤「ENMD-2076」である。そのほか、慢性関節リウマチ治療の経口活性化合物「2-methoxyestrdiol」と経口活性小分子の細胞周期阻害剤「MKC-1」を開発する。   
本社所在地 9620 Medical Center Drive Suite 300 Rockville MD 20850 USA
代表者氏名 Wei-Wu He 魏偉
代表者役職名 Executive Chairman of the Board 取締役会長
電話番号 +1 240-864-2600
設立年月日 33482
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 50人
url www.casipharmaceuticals.com
nasdaq_url https://www.nasdaq.com/symbol/casi
adr_tso
EBITDA EBITDA(百万ドル) -15.27928
終値(lastsale) 3.78
時価総額(marketcap) 327314921.22
時価総額 時価総額(百万ドル) 284.01930
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 218.08174
当期純利益 当期純利益(百万ドル) -16.11213
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 CASI Pharmaceuticals Inc revenues was not reported. Net loss increased from $4.1M to $9.5M. Higher net loss reflects General and administrative - Gross increase from $1.2M to $5.2M (expense) Research and development -Gross increase of 25% to $3.3M (expense) Change in fair value of contingent right decrease from $3K (income) to $0K.

 CASIのテクニカル分析


 CASIのニュース

   CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer  2020/12/16 12:00:00 PR Newswire
ROCKVILLE, Md., and BEIJING, Dec. 16, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces the appointment of Weihao Xu to the…
   CASI Pharmaceuticals Announces Partner Juventas Completes $65 Million Financing And Initiates Registration Study For CNCT19 (CD19 CAR-T)  2020/11/19 02:00:00 PR Newswire
ROCKVILLE, Md. and BEIJING, Nov. 18, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces partner Juventas has completed the…
   CASI Pharmaceuticals: Q3 Earnings Insights  2020/11/09 08:20:00 Benzinga
Shares of CASI Pharmaceuticals (NASDAQ:CASI) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share fell 40.00% …
   CASI Pharmaceuticals To Report Third Quarter 2020 Financial Results And Host Conference Call November 9, 2020  2020/11/05 12:00:00 PR Newswire
ROCKVILLE, MD., and BEIJING, Nov. 5, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call…
   BioInvent schließt erste Lizenzvereinbarung in Großchina ab, mit Beratung von MSQ Ventures  2020/10/29 17:24:00 PR Newswire
NEW YORK, 29. Oktober 2020 /PRNewswire/ -- M.S.Q. Ventures („MSQ") gab heute bekannt, dass sein Kunde BioInvent International, AB („BioInvent") erfolgreich einen Lizenzvertrag mit CASI Pharmaceuticals, Inc. („CASI") für die Entwicklung und Vermarktung von BI-1206 in der Region Großchina…
   CASI Pharmaceuticals Announces Poster Presentation At The 2020 AABB Virtual Annual Meeting  2020/10/02 11:00:00 PR Newswire
ROCKVILLE, Md. and BEIJING, Oct. 2, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that research conducted at the New York Blood…
   Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Top Emerging Players are Ablyn, Aryogen Farmad, CASI Pharmaceuticals Inc., CELGENE CORPORATION, Celltrion Inc., GlaxoSmithKline plc  2020/09/30 19:24:38 OpenPR
Tumor Necrosis Factor (TNF) Inhibitor Drugs Market By Drug (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, Pipeline Analysis), Application (Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease, Ankylosing Spondylitis, Crohn’s Disease, Plaque Psoriasis, Ulcerative Colitis, Hidradenitis Suppurativa, Juvenile Arthritis, Uveitis, Others), Product (Humira, Enbrel, Remicade,
   CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd  2020/09/29 11:00:00 PR Newswire
ROCKVILLE, Md. and BEIJING, Sept. 29, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced a restructuring of its partnership with…
   CASI Pharmaceuticals, Inc. to Participate in Two Upcoming September Conferences  2020/09/11 11:00:00 PR Newswire
ROCKVILLE, Md. and BEIJING, Sept. 11, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Wei-Wu He, Chairman and Chief Executive…
   CASI Pharmaceuticals Announces Second Quarter 2020 Financial Results  2020/08/10 11:00:00 PR Newswire
ROCKVILLE, Md. and BEIJING, Aug. 10, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results and business highlights for…
   CASI Pharmaceuticals Announces Second Quarter 2020 Financial Results  2020/08/10 11:00:00 PR Newswire
ROCKVILLE, Md. and BEIJING, Aug. 10, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results and business highlights for…
   CASI Pharmaceuticals To Report Second Quarter 2020 Financial Results And Host Conference Call August 10, 2020  2020/08/03 11:00:00 PR Newswire
ROCKVILLE, Md. and BEIJING, Aug. 3, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call…
   CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common Stock  2020/07/22 13:05:00 PR Newswire
ROCKVILLE, Md. and BEIJING, July 22, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten public…
   CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock  2020/07/21 20:01:00 PR Newswire
ROCKVILLE, Md. and BEIJING, July 21, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has commenced an underwritten public…
   CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference  2020/06/02 11:00:00 PR Newswire
ROCKVILLE, Md., and BEIJING, June 2, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Dr. Wei-Wu He, Chairman & CEO will…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 CASIファ―マシュ―ティカルズ CASI CASI Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)